PARIS--(BUSINESS WIRE)--Arterial Remodeling Technologies (“ART”) reported today that it has received regulatory approval in Europe to begin its First-In-Man “ARTDIVA” (Arterial Remodeling Transient DIsmantling Vascular Angioplasty) clinical trial next month at five medical centers. ART’s in vivo data strongly suggest that its next-generation bioresorbable stent is designed to promote positive arterial remodeling.
